Journal
JOURNAL FOR IMMUNOTHERAPY OF CANCER
Volume 9, Issue 11, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/jitc-2021-003323
Keywords
biostatistics; clinical trials as topic; immunotherapy
Categories
Funding
- NHLBI NIH HHS [R01 HL089778] Funding Source: Medline
Ask authors/readers for more resources
In a comparative oncology study, stratified analyses based on patients' baseline characteristics may not be valid or interpretable, especially in immunotherapy studies. This article presents alternative approaches using data from KEYNOTE-189 trial to address the limitations of conventional stratified analyses.
In a comparative oncology study with progression-free or overall survival as the endpoint, the primary or key secondary analysis is routinely stratified by patients' baseline characteristics when evaluating the treatment difference. The validity of a conventional strategy such as a stratified HR analysis depends on stringent model assumptions that are unlikely to be met in practice, especially in immunotherapy studies. Thus, the resulting summary is generally neither valid nor interpretable. This article discusses issues with conventional stratified analyses and presents alternatives using data from KEYNOTE-189, a recent immunotherapy trial for treating patients with metastatic, non-squamous, non-small-cell lung cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available